Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics has seen significant growth in the past few years. From 2024’s valuation of $5.69 billion, it’s projected to increase to $6.11 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. Historical growth in this sector can be credited to factors such as the rise in associated disorders, enhancements in diagnostic techniques, advancement in pharmaceuticals, and growing accessibility to global healthcare services.
In the upcoming years, the market size for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics is projected to see robust growth. It is predicted to hit $8.21 billion in 2029, with a compound annual growth rate (CAGR) of 7.7%. This projected growth during the forecast period can be linked to factors such as telemedicine and remote monitoring, data analytics and AI, patient education and support, and changes in regulatory and reimbursement policies. The period is also expected to see major trends such as personalized therapies, the development of new treatments, minimally invasive diagnostics, and collaborative care models.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Are the Core Growth Drivers Propelling the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Forward?
The escalation in the count of individuals suffering from diabetes is anticipated to fuel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Describing diabetes, it’s a persistent metabolic condition portrayed by raised blood sugar levels, or hyperglycemia, sustained over an extended time. The problem arises from the body’s incapacity to generate a sufficient amount of insulin or effectively utilize the insulin it does produce. EPI treatment, employing pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in patients with diabetes and EPI. It can also boost glycemic control in individuals battling diabetes. For instance, according to The National Health Service (NHS England) in June 2024, a UK government-funded healthcare system, reported an 18% spike in the number of individuals identified by the NHS in England as pre-diabetics, from 3,065,825 in 2022 to 3,615,330 in 2023. Also, in individuals below 40, cases rocketed around 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, this rising count of people grappling with diabetes is sparking the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
What Segment Types Define the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Structure?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Emerging Trends that Are Influencing theExocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry Evolution?
Major firms active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics sector are embracing a strategic partnership model to boost technological synergy and broaden their market influence. A strategic partnership usually signifies a cooperative interaction between multiple organizations, pooling their resources, proficiency and work to fulfill shared goals. For example, in February 2023, Codexis, Inc., a protein engineering organization based in the US, and Nestlé Health Science, a Switzerland-based nutritional science firm, released interim findings from their Phase 1 clinical trial of CDX-7108, an experimental therapy for EPI treatment. The conclusions of this Phase 1 trial set the stage for subsequent research that could majorly enhance the treatment alternatives for EPI patients.
View the full report here:
What Is the Definition of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model